Related Experiment Video
Updated: Jan 17, 2026

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
Published on: May 21, 2018
Sepsis-induced ALI/ARDS beyond supportive care: molecular mechanisms and cutting-edge therapies
Muhammad Qasim Barkat1, Qiao Li2, Majid Manzoor1
1Institute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China; Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences at Ningbo University, Ningbo, China.
Abstract:
Sepsis-induced ALI/ARDS are severe conditions driven by complex molecular and cellular mechanisms, including endothelial dysfunction, immunological dysregulation, epigenetic changes, and oxidative stress. These factors disrupt endothelial integrity and promote cell death, worsening lung injury and respiratory failure. COVID-19-related ARDS, similar to sepsis-induced ALI, is more severe, involving immune dysregulation, cytokine storms, and microthrombi. Despite extensive research, sepsis-induced ALI/ARDS has gained the status of the Bermuda Triangle, as no effective pharmacological treatments are currently available, and supportive therapies remain the mainstay of treatment. Consequently, a critical need exists to explore innovative treatment options. This review highlights the molecular and cellular mechanisms of sepsis-induced ALI/ARDS, key cellular signaling pathways in sepsis-induced ALI/ARDS, clinical insights into COVID-19-related ALI/ARDS, existing and emerging treatments, and the limitations of current therapies. It emphasizes the need for innovative approaches to improve patient outcomes and underscores the importance of advancing research to enhance understanding and treatment development.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Heart Failure VI: Adjunct Therapies
Gene Regulation in Microbial Communities: Quorum Sensing
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Cardiopulmonary Resuscitation IV: Pharmacological Management

